CY1119674T1 - Θεραπεια και προληψη της νοσου αλτσχαϊμερ (ad) - Google Patents
Θεραπεια και προληψη της νοσου αλτσχαϊμερ (ad)Info
- Publication number
- CY1119674T1 CY1119674T1 CY20171101303T CY171101303T CY1119674T1 CY 1119674 T1 CY1119674 T1 CY 1119674T1 CY 20171101303 T CY20171101303 T CY 20171101303T CY 171101303 T CY171101303 T CY 171101303T CY 1119674 T1 CY1119674 T1 CY 1119674T1
- Authority
- CY
- Cyprus
- Prior art keywords
- prevention
- alzheimer
- disease treatment
- treatment
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166354 | 2014-04-29 | ||
| EP14166355 | 2014-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119674T1 true CY1119674T1 (el) | 2018-04-04 |
Family
ID=53039896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101303T CY1119674T1 (el) | 2014-04-29 | 2017-12-13 | Θεραπεια και προληψη της νοσου αλτσχαϊμερ (ad) |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10478454B2 (https=) |
| EP (2) | EP3269376B1 (https=) |
| JP (1) | JP6692755B2 (https=) |
| KR (1) | KR102388363B1 (https=) |
| CN (1) | CN106659738B (https=) |
| AU (1) | AU2015254663B2 (https=) |
| CA (1) | CA2946928C (https=) |
| CY (1) | CY1119674T1 (https=) |
| DK (1) | DK3137093T3 (https=) |
| ES (2) | ES2824763T3 (https=) |
| HR (1) | HRP20171896T1 (https=) |
| HU (1) | HUE037501T2 (https=) |
| LT (1) | LT3137093T (https=) |
| NO (1) | NO3137093T3 (https=) |
| PL (1) | PL3137093T3 (https=) |
| PT (1) | PT3137093T (https=) |
| SI (1) | SI3137093T1 (https=) |
| WO (1) | WO2015165966A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102460465B1 (ko) | 2014-04-29 | 2022-10-27 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병（ａｄ）의 치료 및 예방 |
| FI3137094T3 (fi) | 2014-04-29 | 2023-03-20 | Advantage Therapeutics Inc | Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3440593A (en) * | 1993-01-14 | 1994-08-15 | Nelson Arispe | Methods and compositions for blocking amyloid protein ion channels |
| WO1999009981A1 (en) * | 1997-08-21 | 1999-03-04 | P.N. Gerolymatos S.A. | Use of phanquinone for the treatment of alzheimer's disease |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| CA2793580A1 (en) * | 2010-03-29 | 2011-10-06 | Novartis Ag | Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant |
| KR102460465B1 (ko) * | 2014-04-29 | 2022-10-27 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병（ａｄ）의 치료 및 예방 |
| FI3137094T3 (fi) * | 2014-04-29 | 2023-03-20 | Advantage Therapeutics Inc | Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen |
-
2015
- 2015-04-29 LT LTEP15720059.3T patent/LT3137093T/lt unknown
- 2015-04-29 HR HRP20171896TT patent/HRP20171896T1/hr unknown
- 2015-04-29 CA CA2946928A patent/CA2946928C/en active Active
- 2015-04-29 US US15/307,082 patent/US10478454B2/en active Active
- 2015-04-29 SI SI201530145T patent/SI3137093T1/en unknown
- 2015-04-29 ES ES17189527T patent/ES2824763T3/es active Active
- 2015-04-29 AU AU2015254663A patent/AU2015254663B2/en active Active
- 2015-04-29 EP EP17189527.9A patent/EP3269376B1/en active Active
- 2015-04-29 WO PCT/EP2015/059339 patent/WO2015165966A1/en not_active Ceased
- 2015-04-29 ES ES15720059.3T patent/ES2651537T3/es active Active
- 2015-04-29 PT PT157200593T patent/PT3137093T/pt unknown
- 2015-04-29 CN CN201580029861.5A patent/CN106659738B/zh active Active
- 2015-04-29 NO NO15720059A patent/NO3137093T3/no unknown
- 2015-04-29 EP EP15720059.3A patent/EP3137093B1/en active Active
- 2015-04-29 KR KR1020167033332A patent/KR102388363B1/ko active Active
- 2015-04-29 JP JP2016565267A patent/JP6692755B2/ja active Active
- 2015-04-29 PL PL15720059T patent/PL3137093T3/pl unknown
- 2015-04-29 HU HUE15720059A patent/HUE037501T2/hu unknown
- 2015-04-29 DK DK15720059.3T patent/DK3137093T3/en active
-
2017
- 2017-12-13 CY CY20171101303T patent/CY1119674T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160145822A (ko) | 2016-12-20 |
| PL3137093T3 (pl) | 2018-06-29 |
| PT3137093T (pt) | 2017-12-19 |
| EP3269376B1 (en) | 2020-07-15 |
| DK3137093T3 (en) | 2017-12-11 |
| SI3137093T1 (en) | 2018-01-31 |
| ES2824763T3 (es) | 2021-05-13 |
| CN106659738A (zh) | 2017-05-10 |
| HUE037501T2 (hu) | 2018-08-28 |
| EP3137093B1 (en) | 2017-09-13 |
| EP3269376A1 (en) | 2018-01-17 |
| ES2651537T3 (es) | 2018-01-29 |
| KR102388363B1 (ko) | 2022-04-19 |
| JP2017518275A (ja) | 2017-07-06 |
| WO2015165966A1 (en) | 2015-11-05 |
| HRP20171896T1 (hr) | 2018-02-23 |
| AU2015254663A1 (en) | 2016-11-10 |
| CA2946928C (en) | 2023-01-31 |
| JP6692755B2 (ja) | 2020-05-13 |
| AU2015254663B2 (en) | 2020-04-02 |
| LT3137093T (lt) | 2017-12-11 |
| NO3137093T3 (https=) | 2018-02-10 |
| EP3137093A1 (en) | 2017-03-08 |
| US10478454B2 (en) | 2019-11-19 |
| US20170049812A1 (en) | 2017-02-23 |
| CA2946928A1 (en) | 2015-11-05 |
| CN106659738B (zh) | 2021-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125136T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CY1124013T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CY1122344T1 (el) | Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων | |
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| CY1122148T1 (el) | Συνθεσεις που περιεχουν βακτηριακα στελεχη | |
| HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
| CY1120373T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| MA45192A (fr) | Traitement d'association | |
| HUE052095T2 (hu) | Keratin kezelési készítmények és eljárások | |
| MX386234B (es) | Vacuna para la malaria. | |
| PT3481846T (pt) | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda | |
| MX2017004473A (es) | Formulaciones de betalactamasa y usos de las mismas. | |
| MX380252B (es) | Crenezumab para usarse en el tratamiento de enfermedad de alzheimer. | |
| WO2019173795A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| HUE063369T2 (hu) | Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben | |
| PT3634415T (pt) | Composições oftalmológicas que compreendem brimonidina e cetotifeno para utilização no tratamento de alergias | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| CY1122784T1 (el) | Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1 | |
| MX2022013283A (es) | Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales. | |
| CY1127309T1 (el) | Ebselen για χρηση στη θεραπεια της νοσου meniep | |
| MX392976B (es) | Composiciones que comprenden cepas bacterianas. | |
| CY1125031T1 (el) | Μεθοδος για γενετικη θεραπεια χρησιμοποιωντας τον ιο aav-xbp1s/gfp και χρηση αυτης στην προληψη και τη θεραπεια της αμυοτροφικης πλευρικης σκληρυνσης | |
| IT201700121764A1 (it) | Composizione per il trattamento e/o la prevenzione di patologie neurodegenerative. | |
| PT3413870T (pt) | Igmesina para utilização no tratamento de doença de alzheimer | |
| WO2015165980A3 (en) | Treatment and prevention of alzheimer's disease (ad) |